Skip to main content
. Author manuscript; available in PMC: 2024 Oct 5.
Published in final edited form as: Allergy. 2022 Sep 1;78(1):258–269. doi: 10.1111/all.15481

FIGURE 6.

FIGURE 6

pEDN and uEDN concentrations increase prior to relapse on benralizumab. pEDN concentrations (purple circles, left y-axis) and uEDN concentrations (orange squares, left y-axis) prior to development of clinical symptoms related to HES disease relapse (black arrow) and/or prior to a rise in AEC (red diamonds, right y-axis)